BriaCell Therapeutics’ (BCTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BriaCell Therapeutics (NASDAQ:BCTX) in a report released on Thursday,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.

BriaCell Therapeutics Price Performance

NASDAQ:BCTX opened at $0.66 on Thursday. The business’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.88. BriaCell Therapeutics has a 52 week low of $0.46 and a 52 week high of $5.97. The company has a market cap of $23.88 million, a PE ratio of -0.56 and a beta of 1.46.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.45. As a group, sell-side analysts expect that BriaCell Therapeutics will post -1.01 EPS for the current fiscal year.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics as of its most recent SEC filing. Institutional investors own 15.42% of the company’s stock.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.